June 12, 2019
ImmunoPrecise Antibodies (IPA), an industry leader in the discovery of novel, therapeutic monoclonal antibodies, entered into a new antibody discovery collaboration with Entos Pharmaceuticals to develop a therapeutic candidate against an undisclosed, immuno-oncology target, by leveraging ImmunoPrecise’s proprietary B cell Select™ platform. IPAs well-established platform is capable of screening tens of millions of cells, to identify a greater diversity of antibodies, with very little manipulation. This proprietary platform is species and tissue independent, allowing for the generation of antibodies from samples not possible using other methods. The B cell Select ™ platform takes advantage of the diversity of the animal’s immune repertoire, and allows for screening of any protein class, complex therapeutic targets, post-translational modifications, and small molecules.
“Our B cell Select™ platform has a proven track record of discovering large panels of high-affinity antibodies against a broad range of antibody targets, including difficult membrane proteins. Our North American B cell laboratory boasts over one decade of experience with a 94% success rate. This is, in part, why we are very confident in these collaborations, and continue to field requests from such reputable groups,” said Dr. Jennifer Bath, IPA President and CEO. “We are pleased that Entos Pharmaceuticals, a global leader in next generation nucleic acid-based therapies, considers us to be a trusted partner in antibody discovery.”
“The team at Entos is committed to developing breakthrough medicines to address pressing clinical unmet needs,”said Dr. John Lewis, CEO of Entos. “We have been extremely impressed with IPA’s B cell Select™ platform, which provides an ideal approach to develop therapeutic candidates.”
ABOUT IMMUNOPRECISE ANTIBODIES LTD.
ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials. IPA operates from state-of-the-art laboratory facilities located in Victoria, British Columbia and Oss, the Netherlands, and in collaboration with its wholly owned subsidiary U-Protein Express B.V., in Utrecht, the Netherlands. The Company operates globally to offer a continuum of superior antibody services, from target analysis to pre-clinical studies